Each year, the Aspen Brooks team aligns with industry partners to celebrate products making the greatest contributions to the advancement of upstream and downstream bioprocessing.
“We are honoured to be recognised by our industry colleagues for downstream innovation excellence and view this as another signal that our Cadence BioSMB platform is a game-changing product in the industry."
The Cadence BioSMB platform is designed to enhance manufacturing operations and enable users to make a positive impact on global health,” said Mario Philips, VP and General Manager of Pall Biotech.
“This is the second award for the Cadence BioSMB platform, and the sixth for the full Cadence continuous-enabling portfolio since it launched. Through innovation, we will work to continuously improve bioprocesses for today and the future.”
The Cadence BioSMB Process system can be operated in semi- or fully continuous mode to deliver higher throughput efficiency and optimised media utilisation compared with traditional batch or other chromatographic approaches.
Two flow range variants aimed at perfusion (Cadence BioSMB process 80 system) and batch (Cadence BioSMB process 350 system) bioreactor-based processes are available.
In both cases, the unique single-use eight column architecture enables highly flexible flow configurations through the single-use valve cassette.
Additionally, the platform is easy to transition to from existing batch processes with no changes in media or assays and is fully scalable from process development to commercial manufacture.
Peter Levison, PhD, Executive Director Business Development at Pall Biotech highlighted the modularity of the Cadence BioSMB Process 80 and 350 systems at the end of 2017 at the BPI East event.
